ES2284531T3 - Tratamiento nasal topico usando desloratadina y furoato de mometasona. - Google Patents

Tratamiento nasal topico usando desloratadina y furoato de mometasona. Download PDF

Info

Publication number
ES2284531T3
ES2284531T3 ES00968725T ES00968725T ES2284531T3 ES 2284531 T3 ES2284531 T3 ES 2284531T3 ES 00968725 T ES00968725 T ES 00968725T ES 00968725 T ES00968725 T ES 00968725T ES 2284531 T3 ES2284531 T3 ES 2284531T3
Authority
ES
Spain
Prior art keywords
desloratadine
mometasone furoate
nasal
furoate
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00968725T
Other languages
English (en)
Spanish (es)
Inventor
Stephen J. Andrzejewski
William Kreutner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2284531T3 publication Critical patent/ES2284531T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES00968725T 1999-10-08 2000-10-05 Tratamiento nasal topico usando desloratadina y furoato de mometasona. Expired - Lifetime ES2284531T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41508399A 1999-10-08 1999-10-08
US415083 1999-10-08

Publications (1)

Publication Number Publication Date
ES2284531T3 true ES2284531T3 (es) 2007-11-16

Family

ID=23644317

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00968725T Expired - Lifetime ES2284531T3 (es) 1999-10-08 2000-10-05 Tratamiento nasal topico usando desloratadina y furoato de mometasona.

Country Status (9)

Country Link
EP (1) EP1227812B1 (enExample)
JP (3) JP2003511417A (enExample)
AR (1) AR025964A1 (enExample)
AT (1) ATE359784T1 (enExample)
AU (1) AU7859800A (enExample)
CA (1) CA2383970A1 (enExample)
DE (1) DE60034476T2 (enExample)
ES (1) ES2284531T3 (enExample)
WO (1) WO2001026658A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003264859A1 (en) * 2001-12-21 2003-12-19 Sampad Bhattacharya Intranasal pharmaceutical compositions comprising an antihistamine and a leukotriene inhibitor
TR200201343A2 (tr) * 2002-05-17 2003-12-22 Orva İlaç Sanayi̇ Ve Ti̇caret A. Ş. Kortikosteroid ve antiseptik içeren farmasötik bileşim
CA2504200A1 (en) * 2002-11-12 2004-05-27 Alcon, Inc. The use of an anti-allergy agent and a steroid to treat allergic rhinitis
AU2004222340B2 (en) 2003-03-14 2009-11-12 Intersect Ent, Inc. Sinus delivery of sustained release therapeutics
WO2004082589A2 (en) * 2003-03-20 2004-09-30 Ranbaxy Laboratories Limited Nasally administrable, bioavailable pharmaceutical composition of loratadine
TW200522932A (en) * 2003-09-15 2005-07-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
PL2486942T3 (pl) 2004-11-24 2019-05-31 Meda Pharmaceuticals Inc Kompozycje zawierające azelastynę oraz sposoby ich stosowania
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
AU2006231506B2 (en) 2005-04-04 2012-08-30 Intersect Ent, Inc. Device and methods for treating paranasal sinus conditions
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
AU2007272970C1 (en) 2006-07-11 2013-01-10 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
DE102006034883A1 (de) * 2006-07-25 2008-01-31 Hermal Kurt Herrmann Gmbh & Co. Ohg Pharmazeutische Zusammensetzung enthaltend Mometasonfuroat
EP2083798A1 (en) * 2006-10-19 2009-08-05 Cipla Limited Pharmaceutical compositions and nasal spray incorporating anhydrous mometasone furoate
EP2231065B8 (en) 2007-12-18 2021-01-06 Intersect ENT, Inc. Self-expanding devices
CA2732355A1 (en) 2008-08-01 2010-02-04 Intersect Ent, Inc. Methods and devices for crimping self-expanding devices
KR101099826B1 (ko) 2009-02-16 2011-12-27 서울대학교산학협력단 항알러지성 약물을 활성성분으로 함유하는 비강투여용 액상제제
CN106039547A (zh) 2009-05-15 2016-10-26 因特尔赛克特耳鼻喉公司 可展开装置及其使用方法
WO2011141929A2 (en) 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
FR2970180B1 (fr) * 2011-01-06 2013-08-02 Substipharm Dev Procede de preparation de suspensions aqueuses pharmaceutiques comprenant un medicament efficace dans le traitement des rhinites
US9362391B2 (en) 2011-09-21 2016-06-07 Mitsubishi Electric Corporation Silicon carbide semiconductor device and method of manufacturing the same
EP2968877B1 (en) 2013-03-14 2020-01-01 Intersect ENT, Inc. Systems and devices for treating a sinus condition
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
UA116793C2 (uk) 2013-09-13 2018-05-10 Гленмарк Спешіалті С.А. Стабільна фармацевтична композиція з фіксованою дозою, що містить мометазон й олопатадин
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
MX2015009429A (es) 2013-10-04 2015-10-09 Glenmark Pharmaceuticals Ltd Tratamiento de rinitis alergica utilizando una combinacion de mometasona y olopatadina.
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
US20160120928A1 (en) * 2014-11-03 2016-05-05 Zent, Inc. Nasal spray
ES2802530T3 (es) * 2015-08-04 2021-01-20 Windstar Medical Gmbh Una composición nasal
CN106619504A (zh) * 2016-11-10 2017-05-10 北京万全德众医药生物技术有限公司 一种地氯雷他定口服滴剂及其制备方法
CN111787954B (zh) * 2018-02-23 2023-09-05 格兰马克专业公司 使用莫美他松和奥洛他定的组合治疗儿科受试者的过敏性鼻炎
US12303635B2 (en) 2018-04-16 2025-05-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
JP7337791B2 (ja) * 2018-06-22 2023-09-04 参天製薬株式会社 デスロラタジン又はその塩を含有する医薬組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT656206E (pt) * 1991-06-10 2001-11-30 Schering Corp Formulacoes de aerossois sem clorofluorocarbonetos
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
EP0780127A1 (en) * 1995-12-19 1997-06-25 The Procter & Gamble Company A nasal spray containing a steroid and a antihistamine
CA2256721A1 (en) * 1996-06-04 1997-12-11 The Procter & Gamble Company A nasal spray containing an intranasal steroid and an antihistamine
US5939426A (en) * 1997-02-28 1999-08-17 Sepracor Inc. Methods for treating urinary incontinence using descarboethoxyloratadine
JP2001510485A (ja) * 1999-03-01 2001-07-31 シェーリング コーポレイション アトピー性皮膚炎、血管性浮腫および他の障害を抗ヒスタミン薬およびグルココルチコイドを用いて処置するための組成物および方法

Also Published As

Publication number Publication date
EP1227812B1 (en) 2007-04-18
JP2008056698A (ja) 2008-03-13
AR025964A1 (es) 2002-12-26
EP1227812A2 (en) 2002-08-07
WO2001026658A2 (en) 2001-04-19
AU7859800A (en) 2001-04-23
WO2001026658A3 (en) 2002-02-21
DE60034476T2 (de) 2008-01-03
DE60034476D1 (de) 2007-05-31
JP2007106777A (ja) 2007-04-26
ATE359784T1 (de) 2007-05-15
CA2383970A1 (en) 2001-04-19
JP2003511417A (ja) 2003-03-25

Similar Documents

Publication Publication Date Title
EP1227812B1 (en) Topical nasal treatment using desloratadine and mometasone furoate
ES2687751T3 (es) Tratamiento de enfermedades respiratorias
ES2626134T3 (es) Composiciones de bepotastina
JP4680180B2 (ja) 鼻用医薬製剤およびその使用方法
ES2617255T3 (es) Composiciones que comprenden azelastina y métodos de uso de las mismas
ES2738662T3 (es) Composición tópica antifúngica y métodos de tratamiento
ES2891729T3 (es) Composición farmacéutica estable de dosis fija que comprende mometasona y olopatadina para la administración nasal
ES2332290T3 (es) Formulaciones farmaceuticas que comprenden un agonista de beta2 de accion prolongada para su administracion mediante nebulizacion.
ES2935684T3 (es) Formulaciones de epinefrina intranasales y métodos para el tratamiento de enfermedades
JP2013510840A (ja) 口腔乾燥症の治療のためのベタネコールの使用
JP5403868B2 (ja) 鼻用医薬製剤およびその使用方法
JP2008534611A (ja) 抗コリン作用薬、コルチコステロイドおよび長時間作用性βアゴニストを合わせる薬物および方法
CN103260623B (zh) 贝托斯汀组合物
CN103957886B (zh) 稳定的抗炎注射溶液剂
ES2533535T3 (es) Soluciones para inhalación
ES3037198T3 (en) Combination therapy for inhalation administration
CN101951886A (zh) 增强羟甲唑啉的光稳定性
CN103347518A (zh) 含有抗毒蕈碱药物的无推进剂液体制剂
ES2526560T3 (es) Teobromina para el tratamiento de la tos
JP7391026B2 (ja) モメタゾン及びオロパタジンの組み合わせを用いた小児対象におけるアレルギー性鼻炎の治療
CN111643672A (zh) 包含胆碱水杨酸和去氧肾上腺素的液体组合物及其制备方法和用途